Abstract
Nirmatrelvir is the main component of the first oral drug against SARS-CoV-2 called Paxlovid®. Its development from an orally unavailable predecessor through hydrogen bond donors (HBD) replacement is highlighted, followed by an examination of the synthetic routes described in the original PCT application WO2021/250648. Based on its attributes, nirmatrelvir shows the potential to be a game changer in SARS-CoV-2 treatment.
Reference13 articles.
1. World Health Organization – WHO. WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from the originator. Statement. 22 April. 2022. Available at
2. Medicines Patent Pool – MPP. 35 generic manufacturers sign agreements with MPP to produce low-cost, generic versions of Pfizer’s oral COVID-19 treatment nirmatrelvir in combination with ritonavir for supply in 95 low- and middle-income countries. Press Release. 17 March. 2022. Available at
3. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.;Nat Commun,2020
4. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model.;Science,2021
5. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.;ACS Pharmacol Transl Sci,2021
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献